Long‐term outcomes in the second‐line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors
E Jabbour, J Cortes, H Kantarjian - Cancer, 2011 - Wiley Online Library
Chronic myeloid leukemia (CML) is a progressive and often fatal myeloproliferative
neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the …
neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the …
Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors.
E Jabbour, J Cortes, H Kantarjian - Cancer, 2010 - europepmc.org
Chronic myeloid leukemia (CML) is a progressive and often fatal myeloproliferative
neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the …
neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the …
[HTML][HTML] Long-Term Outcomes in the Second-Line Treatment of Chronic Myeloid Leukemia: A Review of Tyrosine Kinase Inhibitors
E Jabbour, J Cortes, H Kantarjian - Cancer, 2011 - ncbi.nlm.nih.gov
Chronic myeloid leukemia (CML) is a progressive and often fatal myeloproliferative
neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the …
neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the …
[引用][C] Long-Term Outcomes in the Second-Line Treatment of Chronic Myeloid Leukemia: A Review of Tyrosine Kinase Inhibitors
E JABBOUR, J CORTES, H KANTARJIAN - Cancer, 2011 - pascal-francis.inist.fr
Long-Term Outcomes in the Second-Line Treatment of Chronic Myeloid Leukemia: A
Review of Tyrosine Kinase Inhibitors CNRS Inist Pascal-Francis CNRS Pascal and Francis …
Review of Tyrosine Kinase Inhibitors CNRS Inist Pascal-Francis CNRS Pascal and Francis …
Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors
E Jabbour, J Cortes, H Kantarjian - Cancer, 2011 - pubmed.ncbi.nlm.nih.gov
Chronic myeloid leukemia (CML) is a progressive and often fatal myeloproliferative
neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the …
neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the …
Long-term outcomes in the second-line treatment of chronic myeloid leukemia: A review of tyrosine kinase inhibitors
E Jabbour, J Cortes, H Kantarjian - Cancer, 2011 - mdanderson.elsevierpure.com
Chronic myeloid leukemia (CML) is a progressive and often fatal myeloproliferative
neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the …
neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the …
Long‐term outcomes in the second‐line treatment of chronic myeloid leukemia
E Jabbour, J Cortes, H Kantarjian - Cancer, 2011 - infona.pl
Chronic myeloid leukemia (CML) is a progressive and often fatal myeloproliferative
neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the …
neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the …
Long-term outcomes in the second-line treatment of chronic myeloid leukemia: A review of tyrosine kinase inhibitors
E Jabbour, J Cortes, H Kantarjian - Cancer, 2011 - augusta.elsevierpure.com
Chronic myeloid leukemia (CML) is a progressive and often fatal myeloproliferative
neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the …
neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the …
[引用][C] Long-term outcomes in the second-line treatment of chronic myeloid leukemia
E Jabbour, J Cortes, H Kantarjian - Cancer, 2010 - cir.nii.ac.jp
Long-term outcomes in the second-line treatment of chronic myeloid leukemia | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …